This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Emmanouilides C , Witzig TE , Wiseman GA , Gordon LI , Wang H , Schilder R , Saville MW , Flinn I , Molina A
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-hodgkin's lymphoma
Cancer Biotherapy and Radiopharmaceuticals. 2007 Oct;22(5) :684-691
AbstractObjective: Treatment-related complications are more common in older patients with non-Hodgkin's lymphoma (NHL), often leading to chemotherapy modifications that can compromise efficacy. We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin((R)) Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL. Design and Methods: Data on safety and efficacy from four clinical trials of Y-90-ibritumomab tiuxetan in 211 patients with NHL were pooled and analyzed by ages of <60, 60-69, and >= 70 years. Results: Patients >= 70 years had a similar incidence of grade 3 or 4 neutropenia (68% vs. 66%), thrombocytopenia (68% vs. 70%), anemia (8% vs. 22%), and nonhematologic adverse events (23% vs. 19%) as that observed in patients <60 years. Response rates (range, 71%-80%) and the durations of response (median of 9.9, 11.0, and 9.4 months) were similar in the three groups. Conclusions: Yttrium-90-ibritumomab tiuxetan produces h!
NotesEmmanouilides, Christos Witzig, Thomas E. Wiseman, Gregory A. Gordon, Leo I. Wang, Hua Schilder, Russell Saville, M. Wayne Flinn, Ian Molina, Arturo MARY ANN LIEBERT INC